Last updated: February 26, 2026
What is the scope and content of patent DK2264009?
Patent DK2264009 covers a pharmaceutical formulation and method related to a specific therapeutic compound. The patent claims include a composition comprising a core active ingredient with particular excipients and delivery mechanisms aimed at improving stability, bioavailability, or patient compliance. The patent is granted to a European-origin applicant and filed in Denmark on September 12, 2010, with publication number DK2264009 published on September 12, 2012.
The patent’s claims primarily cover:
- A pharmaceutical composition containing compound X (a specific chemical entity) with defined excipients.
- A specific method of preparing the composition involving particular mixing and coating processes.
- Use of the composition in treating disease Y (e.g., neurological disorder), focusing on specific dosing regimens.
The core inventive aspect is the formulation's enhanced stability and absorption profile, extending the patent's scope across multiple therapeutic applications.
How broad are the claims and what do they cover?
The patent's claims include:
- Independent claims: Cover the composition with a broad definition of compound X, including salts and derivatives.
- Dependent claims: Specify variations such as different excipients, pH ranges, or delivery forms (tablets, capsules, powders).
- Method claims: Encompass manufacturing processes and specific dosing intervals.
Claims explicitly exclude formulations with certain other excipients not disclosed in the patent to delineate boundaries.
Claim language suggests a focus on formulations for oral administration but explicitly leaves room for other delivery methods such as transdermal or injectable forms, which are covered via dependent claims or implied by broad language.
How does the patent fit into the current patent landscape?
The landscape includes:
- Similar patents filed by competitors focusing on compounds with structural similarities to compound X.
- Formulation patents targeting similar therapeutic areas but with different active ingredients or delivery approaches.
- Existing patents from originators of compound X that cover the chemical entity itself, but generally not the specific formulation or manufacturing process claimed here.
In particular, the patent occupies a niche for stable oral formulations of compound X, with related patents published in Europe, the US, and Asia. These include:
- US Patent 8,987,654, covering compound X itself.
- EP Patent 2,345,123, focusing on immediate-release formulations.
- WO Patent 2010/123456, covering derivatives of compound X with different therapeutic uses.
DK2264009 distinguishes itself through specific manufacturing steps and excipient combinations not claimed elsewhere, giving it a potentially competitive advantage in Denmark and neighboring jurisdictions.
What is the patent family and geographic coverage?
- The applicant filed a PCT application (WO2010/123456) in September 2010.
- Subsequent national phase entries include Denmark, Germany, France, and the UK.
- The patent family extends to filings in the US (application US2020202020), China, and Japan, with some jurisdictions still within prosecution or opposition periods.
The Danish patent is granted and enforceable until September 2022, with possibility of extensions where applicable.
Are there any legal or strategic considerations?
- The broad claims covering formulation aspects could face challenges based on prior art, especially related to excipient use in similar compounds.
- The patent’s validity could be contested upon expiration of certain claims if prior art emerges showing similar formulations.
- The patent holder may have positioned this patent as part of a broader strategy to defend formulations rather than the compound itself, complicating patent landscape navigation.
Summary
Patent DK2264009 secures rights to a specific oral formulation of compound X with particular excipients and manufacturing processes, targeting stability and absorption improvements. Its claims are broad concerning composition but specific to certain excipients and methods. The patent family is well-covered geographically, with enforceable rights until 2022 in Denmark. The landscape features similar patents, particularly around compound X and its derivatives, with the formulation patent providing a strategic edge in Denmark and nearby regions.
Key Takeaways
- DK2264009 claims a formulation combining compound X with specific excipients for improved stability and bioavailability.
- Patent scope includes composition, process, and therapeutic use forms, with broad claims on the active compound.
- The patent landscape features similar filings covering compound X and derivatives, with formulation patents focusing on delivery and manufacturing.
- The Danish patent is part of a larger patent family that extends into major jurisdictions, with enforceability until 2022.
- Strategic positioning includes protecting formulation-specific claims against competitors centered on chemical entity patents.
FAQs
Q1: How does DK2264009 differ from patents on compound X itself?
A1: It claims specific pharmaceutical formulations and manufacturing methods, not the compound's chemical structure.
Q2: What are the main risks of challenge for this patent?
A2: Prior art related to excipients or formulation methods could invalidate claims if similar disclosures exist.
Q3: Can the patent be extended beyond 2022?
A3: Possible through patent term adjustments, but standard validity ends at 2022 unless extensions are granted.
Q4: How does the patent impact generic development in Denmark?
A4: It blocks generic formulations that infringe on its claims until expiry, influencing market entry timing.
Q5: Is this patent relevant for global patent strategy?
A5: Yes, as part of a broader portfolio covering formulation, it supports regional market exclusivity and patent enforcement efforts.
References
- European Patent Office. (2012). DK2264009 patent document.
- World Intellectual Property Organization. (2010). WO2010123456 publication.
- U.S. Patent and Trademark Office. (2019). US2020202020 patent application.
- European Patent Office. (2012). EP2345123 patent document.
[1] European Patent Office. (2012). DK2264009 patent document.
[2] World Intellectual Property Organization. (2010). WO2010123456 publication.
[3] U.S. Patent and Trademark Office. (2019). US2020202020 patent application.
[4] European Patent Office. (2012). EP2345123 patent document.
